Preventing Allergies at the Source

Biologic Medications used to improve the quality of life for the many who suffer from allergic diseases such as Anaphylaxis, Rhinitis, Atopic Dermatitis and IBS. We are the only company positioned to stop Atopic Dermatitis at the source.

About BHT002D™

Explore Our Pipeline

Science with Purpose

We deliver innovation rooted in immunology, driven by a commitment to improving lives.

Science with Purpose

We deliver innovation rooted in immunology, driven by a commitment to improving lives.

Targeted Allergy Prevention

Designed to address allergic responses caused by specific protein allergens.

Targeted Allergy Prevention

Designed to address allergic responses caused by specific protein allergens.

Pipeline Potential

Built with the potential to expand across multiple allergic disease categories.

Pipeline Potential

Built with the potential to expand across multiple allergic disease categories.

Whole-Person Wellness

We treat more than conditions—we support the whole person

Whole-Person Wellness

We treat more than conditions—we support the whole person

Science with Purpose

We deliver innovation rooted in immunology, driven by a commitment to improving lives.

Pipeline Potential

Built with the potential to expand across multiple allergic disease categories.

Targeted Allergy Prevention

Designed to address allergic responses caused by specific protein allergens.

Whole-Person Wellness

We treat more than conditions—we support the whole person

About Bio-Hybrid Therapeutics

Developing the Next Generation of Allergy-Focused Biologic Solutions

🧬

Biologic Innovation

💙

Patient-Centered Mission

🔬

Science-Driven Development

📋

Patent-Pending Technology

🌎

Addressing Global Allergic Disease

Why Bio-Hybrid

A Targeted Approach to a Widespread Problem

Millions of people living with allergic diseases cycle through multiple products, medications, and symptom-management routines without finding lasting relief. Bio-Hybrid Therapeutics is the only company positioned to stop Atopic Dermatitis at the source.

Targets more than symptoms

Complex care made simple

Expansive market opportunity

Built for patients, providers, and partners

Our Solutions

A Focused Pipeline for Allergic Disease

Our portfolio is designed to support patients who suffer from allergic diseases by advancing biologic solutions across multiple indications.

BHT002D™ Lead Biologic Candidate for Atopic Dermatitis

A patent-pending biologic antibody approach intended to help prevent allergic reactive symptoms caused by specific protein allergens. Planning for a Phase 3 clinical study is in progress.

BHT003D™ Topical Biologic Medication

A topical biologic medication concept for Atopic Dermatitis and less severe use cases.

BHT003D™ Topical Biologic Medication

A topical biologic medication concept for Atopic Dermatitis and less severe use cases.

BHT004IB™ Biologic Antibody for IBS

A pipeline candidate exploring biologic applications for IBS-related allergic disease pathways.

BHT004IB™ Biologic Antibody for IBS

A pipeline candidate exploring biologic applications for IBS-related allergic disease pathways.

BHT005GE™ Biologic Antibody for Rhinitisy Care

A targeted biologic approach for patients affected by Rhinitis.

BHT005GE™ Biologic Antibody for Rhinitisy Care

A targeted biologic approach for patients affected by Rhinitis.

BHT006GE™ Biologic Antibody for Shellfish Anaphylaxis

A pipeline candidate focused on severe allergic response prevention.

BHT006GE™ Biologic Antibody for Shellfish Anaphylaxis

A pipeline candidate focused on severe allergic response prevention.

Get Consultation

Interested in learning more about our science, pipeline, or partnership opportunities?

Get Consultation

Interested in learning more about our science, pipeline, or partnership opportunities?

Our Development Approach

How Bio-Hybrid Therapeutics Moves Innovation Forward

Step

1 Identify High-Need Allergic Conditions

We focus on allergic diseases where patients continue to experience major quality-of-life challenges despite existing treatment options.

Step

1 Identify High-Need Allergic Conditions

We focus on allergic diseases where patients continue to experience major quality-of-life challenges despite existing treatment options.

Step

2 Advance Targeted Biologic Solutions

Our team develops biologic medication strategies designed to prevent allergic reactive symptoms caused by specific protein allergens.

Step

2 Advance Targeted Biologic Solutions

Our team develops biologic medication strategies designed to prevent allergic reactive symptoms caused by specific protein allergens.

Step

3 Fast Track Phase 3 Clinical Trial by 2027

Our immune globulin therapy offers a targeted approach to allergy prevention - built for today's clinical needs.

Step

3 Fast Track Phase 3 Clinical Trial by 2027

Our immune globulin therapy offers a targeted approach to allergy prevention - built for today's clinical needs.

Step

4 Expand Through a Focused Pipeline

Our product portfolio focuses on the future of allergy relief so you can feel confident eating, traveling, and living fully - without the constant fear of allergic reactions

Step

4 Expand Through a Focused Pipeline

Our product portfolio focuses on the future of allergy relief so you can feel confident eating, traveling, and living fully - without the constant fear of allergic reactions

FAQs

Frequently Asked Questions

What is Bio-Hybrid Therapeutics developing?

Bio-Hybrid Therapeutics is developing biologic medications focused on allergic diseases, including Atopic Dermatitis, Rhinitis, IBS, and anaphylaxis-related allergic reactions.

What is BHT002D™?

BHT002D™ is Bio-Hybrid Therapeutics’ lead patent-pending biologic candidate for Atopic Dermatitis. It is intended to prevent allergic reactive symptoms caused by specific protein allergens.

Is BHT002D™ approved by the FDA?

BHT002D™ is set to begin clinical trials in Summer 2027.

Who is Bio-Hybrid Therapeutics designed to serve?

The primary audience includes healthcare providers, allergists, and immunologists. Secondary audiences include patients with severe or chronic allergic conditions, and tertiary audiences include biotech investors and research institutions.

What makes Bio-Hybrid Therapeutics different?

Bio-Hybrid Therapeutics is focused on prevention, precision, simplicity, and biologic innovation, with a brand voice that balances scientific rigor and human empathy.

The Future of Allergy Relief Starts at the Source

Bio-Hybrid Therapeutics is advancing a focused biologic pipeline designed to improve quality of life for people living with allergic diseases. Our immune globulin therapies offers a targeted approach to allergy prevention — built for today’s clinical needs. Connect with our team to learn more about our science, pipeline, and partnership opportunities.

Bio-Hybrid Therapeutics is advancing a focused biologic pipeline designed to improve quality of life for people living with allergic diseases. Our immune globulin therapies offers a targeted approach to allergy prevention — built for today’s clinical needs. Connect with our team to learn more about our science, pipeline, and partnership opportunities.

Contact Bio-Hybrid Therapeutics